title: Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts.
abstract: We aimed to test if stimulation of both adenosine A2A and A2B receptors is required to produce an effective cardioprotection against reperfusion injury. Isolated rat hearts were subjected to 30-min regional ischemia followed by 2 h of reperfusion. The adenosine A1/A2 receptor agonist 5'-(N-ethylcarboxamido) adenosine (NECA) given at reperfusion reduced infarct size, an effect that was reversed by both the adenosine A2A antagonist SCH58261 and the A2B antagonist MRS1706. The A2B agonist BAY 60-6583 but not the selective A2A agonist CGS21680 reduced infarct size. Interestingly, a combination of BAY 60-6583 and CGS21680 further reduced infarct size. These results suggest that both A2A and A2B receptors are involved in NECA's anti-infarct effect at reperfusion. NECA attenuated mitochondrial swelling upon reperfusion and this was blocked by both SCH58261 and MRS1706, indicating that activation of A2 receptors with NECA can modulate reperfusion-induced mitochondrial permeability transition pore (mPTP) opening. In support, NECA also prevented oxidant-induced loss of mitochondrial membrane potential (DeltaPsi(m)) and matrix Ca2+ overload in cardiomyocytes via both the A2 receptors. In addition, NECA increased mitochondrial glycogen synthase kinase-3beta (GSK-3beta) phosphorylation upon reperfusion and this was again blocked by SCH58261 and MRS1706. In conclusion, A2A and A2B receptors work in concert to prevent reperfusion injury in rat hearts treated with NECA. NECA may protect the heart by modulating the mPTP opening through inactivating mitochondrial GSK-3beta. A simultaneous stimulation of A2A and A2B receptors at reperfusion is required to produce a strong cardioprotection against reperfusion injury.
authors.affiliation: Department of Anesthesiology, The University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
authors.forename: Jinkun
authors.initials: J
authors.lastname: Xi
authors.forename: Rachel
authors.initials: R
authors.lastname: McIntosh
authors.forename: Xiangjun
authors.initials: X
authors.lastname: Shen
authors.forename: SungRyul
authors.initials: S
authors.lastname: Lee
authors.forename: Guillaume
authors.initials: G
authors.lastname: Chanoit
authors.forename: Hugh
authors.initials: H
authors.lastname: Criswell
authors.forename: David A
authors.initials: DA
authors.lastname: Zvara
authors.forename: Zhelong
authors.initials: Z
authors.lastname: Xu
mesh_terms: D019830:Adenosine-5'-(N-ethylcarboxamide) / Q000494:pharmacology; D000818:Animals; D015153:Blotting, Western; D006321:Heart / Q000187:drug effects; D008297:Male; D018613:Microscopy, Confocal; D009206:Myocardium / Q000378:metabolism* / Q000473:pathology; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D043705:Receptor, Adenosine A2A / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D043704:Receptor, Adenosine A2B / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015427:Reperfusion Injury / Q000139:chemically induced / Q000517:prevention & control*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014665:Vasodilator Agents / Q000494:pharmacology
chemical_list: D043705:Receptor, Adenosine A2A; D043704:Receptor, Adenosine A2B; D014665:Vasodilator Agents; D019830:Adenosine-5'-(N-ethylcarboxamide)
references.citation: J Mol Cell Cardiol. 2007 Nov;43(5):564-70
references.pmid: 17931653
references.citation: Cardiovasc Res. 2004 Feb 15;61(3):372-85
references.pmid: 14962470
references.citation: Anesthesiology. 2008 Feb;108(2):243-50
references.pmid: 18212569
references.citation: Cardiovasc Drugs Ther. 2003 Sep-Nov;17(5-6):415-25
references.pmid: 15107596
references.citation: J Mol Cell Cardiol. 2004 Mar;36(3):411-21
references.pmid: 15010280
references.citation: J Mol Cell Cardiol. 2007 Sep;43(3):262-71
references.pmid: 17632123
references.citation: Am J Physiol. 1996 May;270(5 Pt 2):H1655-61
references.pmid: 8928871
references.citation: Am J Physiol Heart Circ Physiol. 2005 Mar;288(3):H1290-5
references.pmid: 15528225
references.citation: Cardiovasc Res. 2003 Dec 1;60(3):617-25
references.pmid: 14659807
references.citation: Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H1825-33
references.pmid: 18757481
references.citation: Cardiovasc Res. 2007 Jul 15;75(2):426-33
references.pmid: 17570352
references.citation: Am J Physiol Heart Circ Physiol. 2007 Oct;293(4):H2523-9
references.pmid: 17675570
references.citation: J Pharmacol Exp Ther. 1997 Jan;280(1):301-9
references.pmid: 8996210
references.citation: Cardiovasc Res. 2005 Mar 1;65(4):803-12
references.pmid: 15721860
references.citation: Biophys J. 2000 Jul;79(1):39-50
references.pmid: 10866936
references.citation: Am J Physiol. 1996 Oct;271(4 Pt 2):H1456-64
references.pmid: 8897940
references.citation: Eur J Pharmacol. 2009 Feb 14;604(1-3):111-6
references.pmid: 19135050
references.citation: Circulation. 2008 May 27;117(21):2761-8
references.pmid: 18490522
references.citation: Cardiovasc Res. 2005 Jul 1;67(1):124-33
references.pmid: 15949476
references.citation: Biochem J. 1995 Apr 1;307 ( Pt 1):93-8
references.pmid: 7717999
references.citation: J Cardiovasc Pharmacol. 1993 Jul;22(1):89-96
references.pmid: 7690102
references.citation: Basic Res Cardiol. 2006 Jul;101(4):319-26
references.pmid: 16604438
references.citation: Cardiovasc Res. 2006 May 1;70(2):308-14
references.pmid: 16545350
references.citation: Am Heart J. 1992 Feb;123(2):332-8
references.pmid: 1736567
references.citation: Circ Res. 1995 Feb;76(2):242-51
references.pmid: 7834835
references.citation: Circ Res. 2002 Mar 8;90(4):390-7
references.pmid: 11884367
references.citation: Circulation. 2005 Jan 18;111(2):194-7
references.pmid: 15642769
references.citation: Am J Physiol Heart Circ Physiol. 2008 Dec;295(6):H2328-35
references.pmid: 18849340
references.citation: J Cardiovasc Pharmacol. 2001 Sep;38(3):474-81
references.pmid: 11486252
references.citation: Circ Res. 2003 Aug 22;93(4):292-301
references.pmid: 12933700
references.citation: Circulation. 2007 Mar 27;115(12):1581-90
references.pmid: 17353435
references.citation: J Pharmacol Exp Ther. 2006 Jul;318(1):124-31
references.pmid: 16611852
references.citation: Am J Physiol Heart Circ Physiol. 2008 Sep;295(3):H1288-H1295
references.pmid: 18660452
references.citation: Naunyn Schmiedebergs Arch Pharmacol. 2000 Nov;362(4-5):382-91
references.pmid: 11111832
references.citation: J Mol Cell Cardiol. 2001 Jan;33(1):57-68
references.pmid: 11133223
references.citation: Cardiovasc Res. 1997 May;34(2):337-47
references.pmid: 9205548
references.citation: J Mol Cell Cardiol. 2006 May;40(5):708-16
references.pmid: 16516918
references.citation: Pharmacol Rev. 1997 Dec;49(4):381-402
references.pmid: 9443164
references.citation: J Clin Invest. 2004 Jun;113(11):1535-49
references.pmid: 15173880
references.citation: Am J Physiol Heart Circ Physiol. 2008 Nov;295(5):H2079-86
references.pmid: 18805899